Fifteen BC Cancer researchers and clinicians included on Clarivate’s Highly Cited Researchers 2020 list

Fifteen BC Cancer clinicians and scientists have been named in Clarivate’s Highly Cited Researchers 2020 list announced last week. Each has been ranked in the top one per cent in their fields using a method of data and analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information at Clarivate.

For BC Cancer, those fields include clinical medicine, molecular biology and genetics, and cross-field a category which recognizes influence across several fields.

BC Cancer scientists partnering with Microsoft’s artificial intelligence (AI) experts to develop the next generation of cancer imaging and treatment tools

Reading cancer imaging tests may become more straightforward and informative for BC Cancer radiologists thanks to a new research partnership between BC Cancer and Microsoft’s AI for Health program. In this partnership, a group of data and computer scientists at Microsoft will be working alongside Dr. Arman Rahmim, senior scientist at the BC Cancer Research Institute (BCCRI), and Dr. Ivan Klyuzhin, research programmer at BCCRI. Together the team will be developing AI algorithms to assist radiologists and cancer researchers in detection and assessment of tumours in PET/CT images.

New study identifies a strategy to overcome drug resistance in pancreatic cancer

Approximately 835 people in British Columbia will be diagnosed with pancreatic cancer this year. While pancreatic cancer remains one of the most deadly cancers, new research recently published in Cell Reports Medicine has identified a new combination treatment that may overcome drug resistance in pancreatic cancer. 

Three BC Cancer research projects receive National Research Council grants

The Government of Canada, through the National Research Council (NRC), is helping businesses and academia work together. In a recent announcement, three BC Cancer researchers have received grant funding to foster new research projects which may lead to important breakthroughs.The funding, totalling over $370,000 combined, is being awarded to Drs. Dedhar, Lum and Holt for game-changing scientific discoveries and technological breakthroughs.

Research finding may lead to new treatment for rare ovarian cancer

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a particularly devastating cancer commonly diagnosed in women in their twenties and often has a very poor prognosis. In a recent study, researchers with the BC Cancer Research Institute have uncovered a metabolic vulnerability present in SCCOHT cells which may be a target for future treatment options. 

Dr. David Scott named to Lymphoma Research Foundation scientific advisory board

The Lymphoma Research Foundation (LRF) is the largest non-profit lymphoma research organization in North America with a volunteer scientific advisory board comprised of world-renowned lymphoma experts, including Dr. David Scott. Dr. Scott is the clinical director of the BC Cancer Centre for Lymphoid Cancer, deputy head of the BC Cancer Lymphoid Cancer Research and an associate professor at the University of British Columbia. Dr.

Back to top